The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on

Continue Reading

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

(Click on drug name to go to MPR monograph.)  D IND ITX CI W/P ADR HS MFR
AURYXIA (Ferric iron) X X
BOTOX (Onabotulinumtoxin A) X X X
EVOTAZ (Atazanavir/cobicistat) X X
EYLEA (Aflibercept) X X X
GILENYA (Fingolimod (as HCl)) X X
LANOXIN (Digoxin) X X
LANTUS (Insulin glargine (rDNA origin)) X X X X X
OXAYDO (Oxycodone HCl) X X X
OXYTROL (Oxybutynin) X X X
TRILIPIX (Fenofibric acid (as choline fenofibrate)) X X X X X X
VIEKIRA PAK (Ombitasvir/paritaprevir/ritonavir) X
Review more drug monograph updates